Evaluating the Cost Effectiveness of Rapid Diagnostic Testing for the Identification of Pathogens and Resistance Genes in Bloodstream Infections
The model demonstrated improved patient survival and reduced average total costs with mRDT. The Cobas Eplex BCID panels, which have the largest pathogen coverage, reduced both mortality and overall costs compared with other mRDTs.
Authors
- Adam Thornberg
- James Karichu (ORCID: https://orcid.org/0000-0002-2052-4659)
- Xiyu Bao (ORCID: https://orcid.org/0009-0002-5847-0876)
- Tiffeny T. Smith
- Kate Lander
- Mark Pennington (ORCID: https://orcid.org/0000-0003-0508-9828)
Institutions
- Roche (United States) (US)
- Office Of Health Economics (GB)
- Materials Systems (United States) (US)
- La Roche College (US)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1007/s40273-026-01608-1
- Citations
- 1
- Primary Topic
- Bacterial Identification and Susceptibility Testing
- Type
- article
- Field-Weighted Citation Impact
- 41.00